There are 412 resources available
188P - A health-related quality-of-life (HRQoL) analysis from DESTINY-Breast04: Trastuzumab deruxtecan (T-DXd) vs capecitabine (CAP) in patients (Pts) with hormone receptor-positive (HR+), HER2-low metastatic breast cancer (mBC)
Presenter: Andrea Gombos
Session: Lunch and Poster Display session
189P - The impact of high body mass index (BMI) on the safety and efficacy of sacituzumab govitecan (SG) in patients (pts) with metastatic triple-negative breast cancer (mTNBC) from ASCENT
Presenter: Laura García Estevez
Session: Lunch and Poster Display session
190P - French real-world safety and effectiveness of trastuzumab deruxtecan (T-DXd) in the treatment of patients (pts) with HER2+ metastatic or unresectable breast cancer (m/u BC): First results of REALITY-01 ambispective study
Presenter: Jean-Yves Pierga
Session: Lunch and Poster Display session
191P - Use and outcomes of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer in real-world setting: A nationwide cohort study
Presenter: Antonio Di Meglio
Session: Lunch and Poster Display session
192P - Safety and efficacy of trastuzumab deruxtecan and concomitant radiation therapy in patients with metastatic HER2-positive breast cancer
Presenter: Icro Meattini
Session: Lunch and Poster Display session
193P - Efficacy of sacituzumab govitecan versus treatment of physician’s choice in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: A meta-analysis of TROPiCS-02 and EVER-132-002 trials
Presenter: Oleg Gluz
Session: Lunch and Poster Display session
194P - Monitoring for pneumonitis due to trastuzumab deruxtecan (T-DXd): A single centre experience
Presenter: Olivia Walker
Session: Lunch and Poster Display session
195P - Real-life experience of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive advanced breast cancer: A multicentric Portuguese study
Presenter: Rita Bizarro
Session: Lunch and Poster Display session
196P - Surgical axillary intervention after neoadjuvant systemic therapy (NST) for early-stage breast cancer: Clinical significance of micrometastases - Data from five neoadjuvant studies
Presenter: Fabienne Warnecke
Session: Lunch and Poster Display session
197P - Malignant pleural effusion derived metastatic breast cancer cells as an ex vivo model for personalized drug response
Presenter: Zhanna Dauyey
Session: Lunch and Poster Display session